Format

Send to

Choose Destination
Trends Immunol. 2013 Nov;34(11):548-55. doi: 10.1016/j.it.2013.07.004. Epub 2013 Aug 13.

A balance of interleukin-12 and -23 in cancer.

Author information

1
Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research, Herston, 4006, Queensland, Australia.

Abstract

Interleukin (IL)-12 and IL-23 share the IL-12p40 molecule. IL-12 promotes T helper (Th)1 immunity and IL-23 promotes Th17 immunity, and it has recently become apparent that the balance between IL-12 and IL-23 is important in carcinogenesis. A series of studies demonstrated that, where tumor initiation, growth, and metastasis are concerned, IL-12 may act independently of interferon (IFN)-γ, and IL-23 independently of IL-17A. This review explores the activity of IL-23 in carcinogenesis. In the context of the tumor-inhibitory effects of IL-12, and tumor-promoting effects of IL-23, we discuss the use of anti-IL-12p/23 monoclonal antibodies (mAbs) in autoimmune inflammatory disorders and the alternative specific neutralization of IL-23.

KEYWORDS:

autoimmunity; cancer; cytokine; inflammation

PMID:
23954142
DOI:
10.1016/j.it.2013.07.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center